Kyaw Thein

Hematology | Oncology

3730 S Eastern Ave
Las Vegas, NV 89169

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Facial palsy Revealing AR+/HER2+ Parotid carcinoma and the efficacy of HER2-Targeted therapy trastuzumab deruxtecan.

Facial palsy Revealing AR+/HER2+ Parotid carcinoma and the efficacy of HER2-Targeted therapy trastuzumab deruxtecan.

Journal: Oral oncology

Published: August 17, 2026

Biomarker-Stratified Efficacy of Immune Checkpoint Inhibitors in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Trials.

Biomarker-Stratified Efficacy of Immune Checkpoint Inhibitors in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Trials.

Journal: Cancers

Published: April 14, 2026

Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?

Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?

Journal: Cancers

Published: April 11, 2026

Pernicious Anemia: Basic Pathophysiology and Diagnostic Challenges in Neuropsychiatric Patients.

Pernicious Anemia: Basic Pathophysiology and Diagnostic Challenges in Neuropsychiatric Patients.

Journal: Hematology reports

Published: March 04, 2026

Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies.

Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies.

Journal: Cancers

Published: January 31, 2026

Evidence and gaps in tumor-agnostic therapies for breast cancer: a narrative review.

Evidence and gaps in tumor-agnostic therapies for breast cancer: a narrative review.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: November 01, 2025

Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions.

Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions.

Journal: Oncology research

Published: May 13, 2025

HSR25-186: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Risk of General Systemic Adverse Events in Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors.

HSR25-186: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Risk of General Systemic Adverse Events in Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2025

HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Immunochemotherapy.

HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Immunochemotherapy.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 29, 2025

HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab.

HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.

HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

HSR25-176: Efficacy of Immunochemotherapy in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials (RCTs).

HSR25-176: Efficacy of Immunochemotherapy in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials (RCTs).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

Showing 1-12 of 77

Last Updated: 09/26/2026